Skip to content

Peptides / MOTS-c

Panel: recommendedMitochondrial peptideNot FDA approved

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in the DNA of mitochondria, the cell's energy factories, rather than in the main genome. It was discovered in 2015. Natural levels in the blood rise with exercise and fall with age, which is why it is marketed as an exercise mimic.

Reviewed for
Obesity and osteoporosis
Committee vote
7 yes, 5 no, 2 abstain
Strongest evidence
Animals
Legal to compound in the US
Not yet

Effects studied or claimed

What it is promoted for, and where each effect has actually been seen

  • Better blood-sugar control and insulin sensitivityAnimals
  • Protection against weight gain on a fatty dietAnimals
  • Better physical performance in older miceAnimals
  • Stronger bones in osteoporosis modelsAnimals

How it is thought to work

It switches on AMPK, the cell's fuel sensor that exercise also activates. That pushes muscle cells to burn more sugar and fat.

What the evidence shows

In animals and the lab

Fairly consistent results in mice on weight gain, blood sugar and endurance.

In people

Limited. Most human research only measures natural MOTS-c levels in the blood. A drug based on it, CB4211, reached early human trials for fatty liver and obesity, but its developer did not take it further. A registered trial had no posted results when the FDA reviewed it.

Safety and unknowns

Unknown in humans. The weight effects seen in mice have not been shown in people, and nothing suggests it comes close to approved obesity medicines such as tirzepatide or semaglutide.

FDA review

Reviewed for obesity and osteoporosis. FDA staff recommended against it. The committee voted 7 to 5, with 2 abstentions, in favour.

Committee votes are advice to the FDA. A peptide can only be compounded legally once the FDA adds it to the 503A bulks list through formal rulemaking, which has no fixed deadline.

Sources

Analysis

An exercise signal from inside the mitochondria

Peptide Evidence IndexBiology 7/10In people 2.5/10Index 3.6, rank 7 of 15See the full index

MOTS-c is unusual: it is encoded by DNA inside the mitochondria, the cell's power plants, rather than in the nucleus. It was discovered at the University of Southern California in 2015, when researchers showed that giving it to mice on a high-fat diet prevented weight gain and insulin resistance (Lee and colleagues, Cell Metabolism).

A 2021 study in Nature Communications added the anti-ageing angle. Older mice treated with MOTS-c ran further and had better muscle function, and in people, levels of the peptide rose in muscle and blood after exercise (Reynolds and colleagues). That is why it is often described as an exercise mimetic. The closest human drug data come from CB4211, a modified version developed by CohBar. In a four-week trial in 20 people with obesity and fatty liver, it lowered the liver enzymes ALT and AST and blood glucose against placebo, but liver fat fell by a similar amount in both groups.

Our view. MOTS-c is real biology with good-quality mouse papers. The only controlled human data are on a modified analogue, short and small, and they do not yet support the metabolic claims made for the research-grade peptide.

Studies and reports cited

  1. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 2015
  2. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun, 2021
  3. CohBar: topline results of the Phase 1a/1b study of CB4211, August 2021

Summary of published research for general information. It is not medical advice and not a recommendation to use this substance.

← KPVAll peptidesSemax →

General information, not medical advice. Do not buy or inject unregulated peptides.